2002 Aug;77(8):754-9
Dutkiewicz G, Binczak-Kuleta A, Pawlik A, Safranow K, Wisniewska M, Ciechanowicz A, et al
During a median follow-up of 5.4 (IQR 5.15.9) years, patients with a 1.5 mg/week subcutaneous injection of dulaglutide showed a lower incidence rate of the primary composite outcome including non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes ( HR = 0.88, 95% CI 0.790.99, P = 0.026) [62]
As many of you know, in addi
Formulated in a stabilized pre-mixed injection pen for SubQ administration , AOD-9604 ensures high systemic bioavailability and consistent plasma levels in controlled environments
2.11 Statistical Analysis All analyses were repeated three times independently